Supporting Information

Pastori et al. 10.1073/pnas.1424220112

SI Materials and Methods

Human Samples Collection. Control postmortem brain samples were purchased from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland. Control brain specimens from epileptic patients and glioblastoma samples were obtained from the Florida Center for Brain Tumor Research (IRB 134–2006). Additional glioblastoma samples were obtained through the University of Miami Miller School Of Medicine (IRB 20120067).

Helicos SMS. Total, DNase-treated, and rRNA-depleted RNA from glioblastoma and control samples was sequenced using the Helicos single-molecule system essentially as described previously (1, 2).

RNA Extraction and RT-qPCR. The RNA was extracted from tissues using the TRIzol-Chloroform protocol followed by a purification step with columns (QIAGEN RNAeasy Kit) and DNase treatment. cDNA was synthesized according to the manufacturer's protocol (Applied Biosystem cat. no. 4368814) and amplified using TaqMan Gene Expression Assays (Life Technologies). qPCR data were analyzed by Comparative Cq Method ($\Delta\Delta$ Cq).

siRNA Transfections. Gene silencing was achieved by reverse transfection of siRNA using lipofectamine RNAiMax (Invitrogen cat. no. 13778–100) according to the manufacturer's protocol. siRNAs were purchased from Ambion [siHOTAIR1 (3), siHOTAIR2 (3), siBRD4-s23901, siBRD3-s15545, and siBRD2-s12070] and the control siRNA from Qiagen (SI03650318).

Proliferation and Apoptosis Assays. Proliferation was tested by a clonegenic assay plating of transfected cells at low confluency. The colonies were stained with crystal violet after 2 wk. The number of cells in S-phase was determined by incorporation of EdU in transfected cells and imaged using the Click-iT EdU Imaging Kit Alexa594 (Molecular Probes cat. no. C10339). The measurement of late and early apoptotic cells was done by staining the cells with APC Annexin V (BD Pharmigen cat. no. 550474) and 7-AAD (BD Pharmigen cat. no. 559925) and then analyzing them by flow cytometry.

Lentiviral Vector Cloning and Lentivirus Production. shControl and shHOTAIR (sequences below) were cloned in the lentiviral vector pLentiLox3.7. Lentiviral particles were produced cotransfecting LentiX293 cells with pLL3.7, paPAX2, and pVSVG.

The following shControl sequences were used: sense strand, TGCGGTAACTCCACTCAATATTCAAGAGATATTGAGT-GGAGTTACCGCTTTTTTC; antisense strand, TCGAGAAA-

- Kapranov P, et al. (2010) The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol 8:149.
- St Laurent G, et al. (2013) Genome-wide analysis of A-to-I RNA editing by singlemolecule sequencing in Drosophila. Nat Struct Mol Biol 20(11):1333–1339.
- Rinn JL, et al. (2007) Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129(7):1311–1323.
- Ozawa T, James CD (2010) Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp 41:1986.

AAAGCGGTAACTCCACTCAATATCTCTTGAATATTGA-GTGGAGTTACCG. The following shHOTAIR sequences were used: sense strand, TGCAGATGGAGATTACCATTATCAA-GAGTAATGGTAATCTCCATCTGCTTTTTTC; antisense strand, TCGAGAAAAAAGCAGATGGAGATTACCATTAC-TCTTGATAATGGTAATCTCCATCTGCA.

The inducible lentiviral vector to overexpress HOTAIR (pLVX-mCMV-rtTA-TightPromoter-HOTAIR-IRES-ZsGreen) was purchased from Creative Biogene. The expression of HOTAIR was induced by DOX (5 µg/mL).

Luciferase-Expressing Cells and in Vivo Experiments. U87MG cells were transduced with Firefly Luciferase Lentivirus (Capital Biosciences). U87MGLuc cells were transduced with lentivirus expressing shControl or shHOTAIR, and the efficiency of transduction was confirmed by the expression of GFP (reporter of the pLL3.7 vector) visible at the fluorescence microscope. A previously published protocol was used to assess tumor growth (4). NU/NU-Nude mice (Crl:NU-Foxn1^{nu}; Charles River) were anesthetized, and a sagittal incision over the parieto-occipital bone was performed. A 25-gauge needle was used to puncture the skull at 2 mm to the right of the bregma and 1 mm anterior to the coronal suture. Using a 26-gauge Hamilton syringe, 10⁵ cells were injected at 3 mm depth. At 7 and 14 d after the transplant, mice were injected with D-luciferin at 150 mg/kg intraperitoneally (Caliper Life Sciences), anesthetized with isofluorane, and imaged with the IVIS Spectrum Imaging System (Xenogen).

Compounds. I-BET151, JQ1, I-BET762, and TMZ were purchased from Tocris; resuspended in DMSO at a 10 mM concentration; and stored at -80 °C. DOX was purchased from SIGMA (cat. no. D9891) dissolved in H₂O (2 mg/mL) and stored at -80 °C. The Epigenetic library used in this project (Figs. S6 and S7) has been previously described (5, 6).

ChIP. LN18 cells were collected, cross-linked with formaldehyde, and processed using the EZ-Magna ChIP (Millipore cat. no. 17–408) according to the manufacturer's instructions. The chromatin was immunoprecipitated with antibodies for BRD4 (Bethyl Laboratories Inc. cat. no. A301-985A50) and negative control antibody IgG (Millipore, cat. no. 12–370). DNA–protein cross-links were reversed and DNA purified to be used in the quantitative amplification of HOTAIR's promoter with SYBR Green (forward primer, ACCTAATCCGACCAGCAAGA; reverse primer, GGGTGAAGGGAAGTGTCTGA).

 Long J, et al. (2014) The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem 289(51):35494–35502.

Plotkin A, Volmar CH, Wahlestedt C, Ayad N, El-Ashry D (2014) Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. Breast Cancer Res Treat 147(2):249–263.

Principal component analysis (PCA)



Fig. 51. (A) PCA on control and glioblastoma human samples. Separation of normal (blue) and GBM (red) samples in PCA performed on single-molecule expression values from various types of transcripts. The two top dimensions of PC1 and PC2 are shown, (*Left*) exons of UCSC Genes and (*Right*) exons of UCSC genes that have no annotated ORFs (IncRNAs). (*B*) The mRNA expression level of four different housekeeping genes (PPIA, 185, PGK1, and G6PD) has been tested in control and GBM specimens. (C) The expression of MEG3, HOTAIRM1, and DGCR5 has been measured by RT-qPCR, normalizing the values on the housekeeping gene G6PD as alternative to 185, which is reported in Fig. 1*B*. (*D*) RNA extracted from human insula, pons, frontal lobe, temporal lobe, hippocampus, or cerebellum was purchased from Clontech and used to test the expression of HOTAIR that was revealed to be undetectable (*Left*). Amplification curves (quantification of cycles, Cq) of GAPDH are shown (*Right*) to prove RNA integrity.

U

A N A

Color Key

Fig. 52. High-quality figure for the heat map representing the 100 most up-/down-regulated lncRNAs in GBM versus control samples (Fig. 1A).

Q2 (7AAD+/ AnnexinV+)= late apoptosis/necrosis Q4 (7AAD-/AnnexinV+)= early apoptosis

Fig. S3. (A) LN18 cells were transfected with siHOTAIR#1, siHOTAIR#2, and siControl (25 nM), and the RNA was extracted 96 h later to quantify the depletion of HOTAIR by RT-qPCR. (B) HOTAIR was depleted in LN18 with siHOTAIR#1 and siHOTAIR#2, and cells were plated at low confluence (500 per well) to be fixed and stained with crystal violet for a colony forming assay after 2 wk. Three experiments are represented. (C) U87MG cells were transduced with a HOTAIR expressing vector and sorted to obtain a pure population of cells expressing HOTAIR. HOTAIR was induced by DOX. Control cells (–DOX) and HOTAIR-overexpressing cells (+DOX) were transfected with siControl, siHOTAIR#1, and siHOTAIR#2. After 5 d, cells were harvested and stained with annexinV and 7-AAD for viability assay. The percentage of early/late apoptotic cells was determined by flow cytometry.

U87MG

U87MG-Luc shControl

b

U87MG-Luc shHOTAIR

Fig. 54. (*A*) U87MG cells were transduced with lentivirus (shControl and shHOTAIR) to test the proliferation with colony forming assay. (*B*) For the implantation of tumor cells in the mice brain, the luciferase-expressing U87MG cells (U87MGLuc) were transduced with lentivirus, and the efficiency of infection was confirmed by GFP expression visible at the fluorescence microscope. (*C* and *D*) LN18 and U87MG cells were treated with TMZ and I-BET151 for 72 h to collect RNA. HOTAIR (*C*), and *CDKN1A* (*D*) expression was measured by RT-qPCR. (*E*) U87MG cells not expressing the tet-inducible HOTAIR vector were treated with DOX (5 μ g/mL) for 4 d, and then the effects on proliferation were assessed with an EdU imaging kit. The EdU percentage of positive cells was calculated with the Cellomics ArrayScan Reader. (*F*) Fluorescence microscope images of nontransduced U87MG cells treated with +/–DOX and stained with EdU (pink) and Hoechst (blue).

10µM

Q2

8 102

102

¥ **∏** •46

20µM 001-ctr20

10³ 10⁴ nexin V APC-A

Ann

Specimen_001-20

able 0 10³ 10⁴ Annexin V APC-A

Q2

Q2

Control

U87MG

+HOTAIR

2μM DMSO Spec Specimen_001-ctr (Q Q2 7-000-7 8 102 ¥ ₽ -646 nna rihna r 10⁰ 10⁴ nexin VAPC-A ů 10³ 10⁴ nexin V APC-A Specimen_001-2 Specimen_001-0 Q2 °⊆-] Q1 Q2 QI

Q4= early apoptotic cells (Annexin+/7AAD-) Q2= late apoptotic cells (Annexin+/7AAD+)

		C	21	2		
U87MG (5 days)	% Viable (control)	<pre>% Early apoptosis (control)</pre>	<pre>% Late apoptosis (control)</pre>	% Viable (+HOTAIR)	<pre>% Early apoptosis (+HOTAIR)</pre>	<pre>% Late apoptosis (+HOTAIR)</pre>
DMSO	82	12.5	4.7	95	2.1	1
2 μΜ	58	30	10	94	3.2	2.1
10 µM	61	26	10	93	2.9	2.7
20 µм	57	28	12	92	3.3	2.4

ChIP-qPCR: (HOTAIR promoter ~1kB)

PNAS

A-DAP-7

7-AAD-A

10³ 10⁴ exin V APC-A

10

20

Fig. S5. (A) +/-DOX cells were treated with I-BET151 at 2, 10, and 20 μ M for 5 d. To quantify the apoptosis rate by flow cytometry, the cells were incubated with annexinV and 7-AAD. The table reports the percentage of early apoptotic (Q4) and late apoptotic cells (Q2) for every sample. (B) U87MG cells transduced with HOTAIR-expressing lentivirus and treated with +/-DOX and different concentrations of I-BET151 (DMSO, 1 µM, 5 µM, and 10 µM) for 4 d. Proliferation was assessed by EdU staining, and the percentage of proliferating cells was calculated with the Cellomics ArrayScan reader. From these data, the IC₅₀ was calculated for +/-DOX-treated cells. (C) ChIP was performed with BRD4 antibody and IgG as a negative control in LN18 cells 4 d after transfection with siControl and siBRD4. The chromatin obtained by the immunoprecipitation was used for qPCR to amplify the promoter region of HOTAIR located ~1 kb upstream from the transcription start site. The graph shows the fold enrichment of BRD4 on HOTAIR's promoter normalized to the IgG signal.

Epigenetic drugs library

Iricnostatin A	HDAC inhibitor
2,4-Pyridinedicarboxylic Acid	Histone demethylase inhibitor
Garcinol	HAT inhibitor
Splitomicin	SIRT2 inhibitor
BML-210	HDAC inhibitor
Apicidin	HDAC inhibitor
SuberovI bis-hydroxamic acid	HDAC inhibitor
Scriptaid	HDAC inhibitor
Nullscript	Scriptaid Neg control
5-Aza-2'-deoxycytidine (Decitabine)	DNA Me transferase inhibitor
Zebularine	DNA Me transferase inhibitor
Vorinostat (SAHA)	
loopiootinomido	hDAC minibitor
Dhanvihuturata Na	
	HDAC INNIDITOR
	Lysine demethylase inhibitor
EX-52/	SIRII inhibitor
Resveratrol	SIRT1 activator
M-344	HDAC inhibitor
Nicotinamide	SIRT inhibitor
BML-266	SIRT2 inhibitor
Piceatannol	SIRT activator
Fluoro-SAHA	HDAC inhibitor
Valproic acid hydroxamate	HDAC inhibitor
AGK2	SIRT2 inhibitor
Salermide	SIRT inhibitor
MC-1293	HDAC inhibitor
Anacardic acid	HAT inhibitor
B2	SIRT2 inhibitor
BIX-01294·3HCI	Histone methyl transferase inhibitor
Butyrolactone 3	HAT inhibitor
СТРВ	HAT inhibitor
Oxamflatin	HDAC inhibitor
Sirtinol	SIRT inhibitor
Suramin⋅6Na	SIRT1 inhibitor
BML-278	SIRT1 actvator
NOLI 54	
NCH-51	HDAC INNIDITOR
CI-994	HDAC Inhibitor
CI-994 NSC-3852	HDAC Inhibitor HDAC inhibitor HDAC inhibitor
CI-994 NSC-3852 Aminoresveratrol sulfate	HDAC Inhibitor HDAC inhibitor HDAC inhibitor SIRT1 activator
CI-994 NSC-3852 Aminoresveratrol sulfate BML-281	HDAC Inhibitor HDAC inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor
CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol	HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator
CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151	HDAC inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2.3 4 and T inhibitor
CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126	HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor –
CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946	HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor –
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1	HDAC Inhibitor HDAC inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and IMID3 Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4	HDAC Inhibitor HDAC inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide	HDAC Inhibitor HDAC inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76	HDAC Inhibitor HDAC inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases Inhibitor KDM2/7 Histone Demethylases Inhibitor ISD1 Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J4 Daminozide LSD1-C76 ACY1215 (Recilinostat)	HDAC Inhibitor HDAC inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases INX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor –
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907	HDAC Inhibitor HDAC Inhibitor HDAC Inhibitor HDAC- inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– H33(HDAC dual inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101	HDAC Inhibitor HDAC Inhibitor HDAC Inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC (FGER/HER2 Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101 LINC1215	HDAC Inhibitor HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC/EGFR/HER2 Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101 UNC1215	HDAC Inhibitor HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC/EGFR/HER2 Inhibitor L3MBTL3 Domain Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101 UNC1215 UNC669 ACI 5198 (JDH C25)	HDAC Inhibitor HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC/EGFR/HER2 Inhibitor L3MBTL3 Domain Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101 UNC1215 UNC669 AGI-5198 (IDH-C35) ACI 6790	HDAC Inhibitor HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2,3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC/EGFR/HER2 Inhibitor L3MBTL3 Domain Inhibitor Mutant IDH1 Inhibitor
NCI-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101 UNC1215 UNC669 AGI-5198 (IDH-C35) AGI-6780 ML 2	HDAC Inhibitor HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2, 3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC/EGFR/HER2 Inhibitor L3MBTL3 Domain Inhibitor Mutant IDH1 Inhibitor Mutant IDH2 Inhibitor
NCL-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101 UNC1215 UNC669 AGI-5198 (IDH-C35) AGI-6780 MI-2 LOY2	HDAC Inhibitor HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2, 3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC/EGFR/HER2 Inhibitor L3MBTL3 Domain Inhibitor L3MBTL1 Domain Inhibitor Mutant IDH1 Inhibitor Mutant IDH2 Inhibitor
NCC-31 CI-994 NSC-3852 Aminoresveratrol sulfate BML-281 Triacetylresveratrol I-BET151 GSK126 SGC0946 GSK-J1 GSK-J4 Daminozide LSD1-C76 ACY-1215 (Rocilinostat) CUDC-907 CUDC-101 UNC1215 UNC669 AGI-5198 (IDH-C35) AGI-6780 MI-2 IOX2	HDAC Inhibitor HDAC Inhibitor HDAC inhibitor SIRT1 activator HDAC-6 inhibitor SIRT1 activator BRD 2, 3 4 and T inhibitor EZH2 Methyltransferase Inhibitor – DOT1L inhibitor – H3K27 Histone Demethylases UTX and JMJD3 Inhibitor H3K27 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases UTX and JMJD3 Inhibitor KDM2/7 Histone Demethylases Inhibitor LSD1 Inhibitor HDAC6 inhibitor– PI3K/HDAC dual inhibitor HDAC/EGFR/HER2 Inhibitor L3MBTL3 Domain Inhibitor Mutant IDH1 Inhibitor Mutant IDH2 Inhibitor Mutant IDH2 Inhibitor MIEP rolyl-Hydroxylases (PHD2) Inhibitor

Fig. S6. Table of the epigenetic compound library.

AS PNAS PNAS

Cell to Ct: HOTAIR expression

relative gene expression

Fig. S7. We used the LN18 cell line to screen a library of 61 compounds (Fig. S6) acting as inhibitors of epigenetic enzymes such as HDACs, histones acetyl transferases (HATs), DNA methyl transferases, histone demethylase, histone methyl transferases, and histone mark "readers" such as the bromodomain proteins. BET Bromodomain inhibitors and HDAC inhibitors reduce the expression of HOTAIR in vitro. The compounds were applied at the dose of 10 μ M for 24 h on LN18 cells, and the expression of HOTAIR was measured with the Cells-to-Ct Kit (Life Technologies).